|
|
Volumn 28, Issue 3, 2001, Pages 313-314
|
|
T cell-depleted nonmyeloablative stem cell transplantation: What is the optimum balance between the intensity of host conditioning and the degree of T cell depletion of the graft?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
CD3 ANTIGEN;
CD34 ANTIGEN;
FLUDARABINE;
IMMUNOSUPPRESSIVE AGENT;
MELPHALAN;
MYELOABLATIVE AGENT;
THYMOCYTE ANTIBODY;
ADULT;
APHERESIS;
CASE REPORT;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL EXAMINATION;
CLINICAL FEATURE;
CLINICAL PROTOCOL;
CONTROLLED STUDY;
FEMALE;
GRAFT FAILURE;
GRAFT VERSUS HOST REACTION;
HUMAN;
IMMUNE RESPONSE;
IMMUNOSUPPRESSIVE TREATMENT;
IN VIVO STUDY;
INCIDENCE;
LETTER;
LYMPHOCYTE DEPLETION;
MALE;
NONHODGKIN LYMPHOMA;
PRIORITY JOURNAL;
STEM CELL TRANSPLANTATION;
T LYMPHOCYTE;
TREATMENT OUTCOME;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
FEMALE;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
LYMPHOCYTE DEPLETION;
MALE;
MIDDLE AGED;
TRANSPLANTATION CONDITIONING;
TRANSPLANTATION, HOMOLOGOUS;
TREATMENT OUTCOME;
|
|
EID: 0034893728
PISSN: 02683369
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.bmt.1703117 Document Type: Letter |
|
Times cited : (10)
|
|
References (6)
|
